Aurora Cannabis (TSX:ACB) revealed its Q4 and 2018 fiscal year results on Monday (September 24), giving investors a closer look at its revenues and upcoming plans to list in the US.

Aurora reported a growth in revenue for the quarter, representing a 223 percent improvement over the same time period last year. The cannabis producer generated C$19.1 million in revenue during Q4.

According to the company, this uptick in revenue was due to a “higher average selling price, per gram of dried cannabis, coupled with a higher proportion of cannabis oil sales.”

The company also indicated in its financials that it expects to produce 150,000 kilograms of cannabis per year at the end of Q2 2019, once all of its licensed facilities are at full capacity.

As part of its expansion, the company secured a C$200 million debt facility with the Bank of Montreal (TSE:BMO) in September. At the end of the quarter the producer held an C$89 million cash position.

US listing will offer new investors chance for cannabis exposure

In its report, the company confirmed a premier US exchange listing is coming. Aurora CEO, Terry Booth, said the listing would give access to a “broader investor audience” the opportunity to participate in the company.

The company will file a registration form with the US Securities and Exchange Commission (SEC) and will seek, pending approval, its proper US exchange.

The company would be joining Canopy Growth (NYSE:CGC,TSX:WEED), Tilray (NASDAQ:TLRY), and Cronos Group (NASDAQ:CRON,TSX:CRON) as Canadian cannabis licensed producers listed across these US exchanges.

Aurora’s pending US listing will arrive following the company’s decision to spin off a separate entity, Australis Capital (CSE:AUSA), which is set to pursue opportunities in the US multistate operator business model.

Australis made its public debut on the Canadian Securities Exchange (CSE) on September 19. Aurora shareholders obtained a stake in the new venture as part of the launch.

During an investor and analyst conference call on Tuesday (September 25), management of the company was asked whether this upcoming US listing will affect the potential for the company to find an established partner outside of cannabis.

Aurora was at the center of rumors of The Coca-Cola Company (NYSE:KO) potentially entering the cannabis space through a partnership looking to develop infused wellness beverages.

Management of the producer was also asked whether the company is inclined to look for a deal in which it retains control or find a partner to take over.

Booth said while it is exciting to see the entry of large companies with no relation to cannabis, Aurora is not “in the mood to be selling out anytime soon.”

“When you start to see the revenues that this company is going to generate on a global basis, then you will see even more attraction coming from these larger companies,” Booth said.

Cam Battley, chief corporate office for Aurora, added the company is well positioned for a deal but is also holding reservation on the type of deal it makes.

In terms of the US listing moving the needle for a potential deal with an established player, Battley said the new investing option “won’t affect things immediately.” Rather, Battley said, it is seen as a move to allow the entry of more investors.

Investor takeaway

Stock for Aurora quickly increased in value during Tuesday’s early trading session. The company rose to a share price of C$12.92, indicating a 5.30 percent increase, as of 1:25 p.m. EST.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less